X

Vous n'êtes pas connecté

Maroc Maroc - DRUGS.COM - Clinical Trials News - 22/Jun 04:06

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of...

Articles similaires

Sorry! Image not available at this time

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

drugs.com - 17/Jun 23:06

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 17, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY...

Sorry! Image not available at this time

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

financialpost.com - 23/Jun 16:08

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161...

Sorry! Image not available at this time

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

financialpost.com - 21/Jun 20:01

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU...

Sorry! Image not available at this time

Takeda Announces New Assignments of Directors

financialpost.com - 26/Jun 07:13

OSAKA, Japan — Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the...

Sorry! Image not available at this time

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

drugs.com - 20/Jun 03:06

DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial...

Sorry! Image not available at this time

Promising results from the Phase 2 study of novel extended-release ketamine tablets (R-107) for Treatment-Resistant Depression accepted for publication by Nature Medicine

drugs.com - 24/Jun 23:06

AUCKLAND, New Zealand, June 24, 2024. Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that results from...

Walking and education intervention significantly reduces recurrence of low back pain

news.medical.net - 24/Jun 13:50

Researchers conducted a randomized controlled trial to determine the clinical efficacy and cost-efficiency of the WalkBack personalized, walking, and...

Sorry! Image not available at this time

International Yoga Day 2024: The Impact Of Yogic Practices On Quality Of Life

zeenews.india.com - 21/Jun 10:49

These non-invasive, non-pharmacological techniques encompass meditation-based modalities that offer profound benefits increasingly validated by modern...

Sorry! Image not available at this time

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

drugs.com - 26/Jun 03:06

LUND, Sweden, June 25, 2024. Camurus today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized,...

Immune Response Study Explains Why Some People Don’t Get COVID-19

eurasiareview.com - 19/Jun 22:15

Scientists have discovered novel immune responses that help explain how some individuals avoid getting COVID-19. Using single-cell sequencing,...